Evaluating the Effects of Glucagon-Like Peptide 1 Receptor Agonists as a Secondary Prevention in Peripheral Arterial Disease: A Meta-Analysis | Synapse
February 19, 2026Diabetes Therapy1 citationsOpen Access
Evaluating the Effects of Glucagon-Like Peptide 1 Receptor Agonists as a Secondary Prevention in Peripheral Arterial Disease: A Meta-Analysis
The aim is to evaluate the impact of glucagon-like peptide 1 receptor agonists on outcomes in peripheral arterial disease and diabetes.
Conducted a meta-analysis of randomized trials
Included studies focused on GLP-1 receptor agonists
Examined outcomes like revascularization and amputation
No statistically significant differences observed in revascularization outcomes
No significant differences found in amputation rates among groups receiving GLP-1 RAs
Abstract
In this meta-analysis of randomized trials, GLP-1 RAs were not associated with statistically significant differences in revascularization or amputation outcomes in individuals with diabetes and PAD.